Skip to main content

ARDS

6
Pipeline Programs
9
Companies
7
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
3
1
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
1100%
+ 9 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
cisatracuriumPhase 4
Healios
HealiosJapan - Tokyo
1 program
1
MultiStemPhase 2/31 trial
Active Trials
NCT04367077Unknown400Est. Dec 2023
Orion
OrionUK - Cambridge
1 program
1
Imatinib Mesylate intravenous solutionPhase 21 trial
Active Trials
NCT04794088Terminated67Est. Apr 2022
Orion Pharma
Orion PharmaUK - Reading
1 program
1
Imatinib Mesylate intravenous solutionPhase 2
APEPTICO
APEPTICOAustria - Vienna
1 program
1
SolnatidePhase 2Peptide1 trial
Active Trials
NCT03567577Completed92Est. Dec 2024
Medpace
MedpaceCINCINNATI, OH
1 program
1
AVM0703Phase 1
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
2 programs
EIT-guided PEEP settingN/A1 trial
lung recruitment potential assessed by 3D EITN/A1 trial
Active Trials
NCT04734340Unknown100Est. Jun 2023
NCT06594601Recruiting50Est. Dec 2025
Hamilton medical
Hamilton medicalSwitzerland - Bonaduz
1 program
INTELLiVENT-ASVN/A1 trial
Active Trials
NCT03211494Terminated13Est. Mar 2019
Eppendorf
EppendorfGermany - Hamburg
1 program
Near-infrared spectroscopy-based assessement of cerebral autoregulation.N/A1 trial
Active Trials
NCT03949738Completed66Est. Nov 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
HealiosMultiStem
OrionImatinib Mesylate intravenous solution
APEPTICOSolnatide
UNION therapeuticslung recruitment potential assessed by 3D EIT
UNION therapeuticsEIT-guided PEEP setting
EppendorfNear-infrared spectroscopy-based assessement of cerebral autoregulation.
Hamilton medicalINTELLiVENT-ASV

Clinical Trials (7)

Total enrollment: 788 patients across 7 trials

NCT04367077HealiosMultiStem

MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)

Start: Apr 2020Est. completion: Dec 2023400 patients
Phase 2/3Unknown
NCT04794088OrionImatinib Mesylate intravenous solution

Intravenous Imatinib in Mechanically Ventilated COVID-19 Patients

Start: Mar 2021Est. completion: Apr 202267 patients
Phase 2Terminated
NCT03567577APEPTICOSolnatide

Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS

Start: May 2018Est. completion: Dec 202492 patients
Phase 2Completed
NCT06594601UNION therapeuticslung recruitment potential assessed by 3D EIT

PEEP Titration and Lung Recruitment Potential Assessed by 3D EIT

Start: Jan 2024Est. completion: Dec 202550 patients
N/ARecruiting
NCT04734340UNION therapeuticsEIT-guided PEEP setting

The Study of EIT-guided Ventilation Strategy on ARDS Patients

Start: Jan 2021Est. completion: Jun 2023100 patients
N/AUnknown
NCT03949738EppendorfNear-infrared spectroscopy-based assessement of cerebral autoregulation.

Cerebrovascular Hemodynamics in Patients With ARDS.

Start: Dec 2018Est. completion: Nov 202066 patients
N/ACompleted
NCT03211494Hamilton medicalINTELLiVENT-ASV

Does Automated Closed-Loop Ventilation Reduce the DRiving Pressure Levels in Patients With ARDS

Start: Nov 2017Est. completion: Mar 201913 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 788 patients
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.